BARR'S GENERIC XANAX TABLETS RECEIVE FDA APPROVAL

The FDA has granted final approval to Barr Laboratories' generic versions of Pfizer's panic disorder drug Xanax, the drugmaker said.

Barr said it received approval to market the product, alprazolam extended-release tablets, in 0.5-, 1-, 2- and 3-mg doses. The company intends to launch its product immediately.

Xanax is approved to treat panic disorder, with or without agoraphobia, which is a fear of public places, especially ones from which the patient feels it would be difficult to escape.

Barr cited IMS Health data that indicated sales of Xanax were $83 million during the 12-month period that ended in May.